Baird Medical Investment Holdings (BDMD)
NASDAQ:BDMD
Want to see BDMD full AI Analyst Report?
Top Page
Baird Medical Investment Holdings
(NASDAQ:BDMD)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-14.77% Downside)
Action:N/ADate:04/30/26
The score is primarily held down by deteriorating financial performance (2025 revenue decline, swing to losses) and persistently negative operating/free cash flow. Technical indicators are also weak (below key moving averages and negative MACD), while valuation is difficult to support given the negative P/E tied to losses.
Positive Factors
High Gross Margins
Sustainably high gross margins provide structural pricing flexibility and a larger gross profit buffer versus peers. Over 2–6 months this supports ability to invest in R&D or absorb adverse mix shifts, helping restore operating leverage if revenue stabilizes.
Negative Factors
Revenue Decline & Losses
A ~29% revenue decline and a swing to deep operating losses materially weaken sustainable earning power. Over months this erodes margins, reduces pricing leverage, and undermines recovery prospects unless demand or commercial execution meaningfully improves.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustainably high gross margins provide structural pricing flexibility and a larger gross profit buffer versus peers. Over 2–6 months this supports ability to invest in R&D or absorb adverse mix shifts, helping restore operating leverage if revenue stabilizes.
Read all positive factors
Baird Medical Investment Holdings (BDMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$73.35M
Dividend YieldN/A
Average Volume (3M)238.60K
Price to Earnings (P/E)―
Beta (1Y)-0.93
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees148
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,979,380
10 Day Avg. Volume117,298
30 Day Avg. Volume238,602
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.68
P/FCF Ratio-27.26
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda-3.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Baird Medical Investment Holdings Business Overview & Revenue Model
Company Description
Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China. The company's medical devices are used for treatment of benign and mal...
Baird Medical Investment Holdings Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.54M | 37.04M | 31.46M | 35.09M | 27.72M |
| Gross Profit | 18.88M | 32.65M | 27.23M | 28.04M | 23.18M |
| EBITDA | -24.53M | 16.17M | 12.88M | 16.29M | 14.16M |
| Net Income | -27.28M | 12.45M | 10.55M | 12.57M | 11.68M |
Balance Sheet | |||||
| Total Assets | 69.70M | 77.96M | 56.71M | 42.62M | 26.12M |
| Cash, Cash Equivalents and Short-Term Investments | 178.32K | 2.97M | 1.63M | 1.91M | 3.44M |
| Total Debt | 19.30M | 20.88M | 9.90M | 7.44M | 2.93M |
| Total Liabilities | 38.48M | 38.20M | 21.00M | 16.84M | 10.26M |
| Stockholders Equity | 31.37M | 39.66M | 35.75M | 25.93M | 5.20M |
Cash Flow | |||||
| Free Cash Flow | -1.39M | -9.17M | -3.66M | -5.47M | 3.87M |
| Operating Cash Flow | -1.34M | -6.31M | -1.02M | 485.97K | 5.26M |
| Investing Cash Flow | -42.31K | -2.85M | -2.64M | -5.92M | -1.39M |
| Financing Cash Flow | -1.39M | 10.72M | 3.46M | 4.41M | -1.93M |
Baird Medical Investment Holdings Risk Analysis
Baird Medical Investment Holdings disclosed 82 risk factors in its most recent earnings report. Baird Medical Investment Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Baird Medical Investment Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $76.96M | 22.00 | 10.27% | ― | 14.21% | ― | |
52 Neutral | $128.00M | -13.16 | -117.54% | ― | 9.86% | 58.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $130.06M | -4.20 | -111.74% | ― | ― | ― | |
48 Neutral | $115.12M | -2.88 | -317.03% | ― | ― | 0.28% | |
47 Neutral | $20.70M | -2.58 | -221.04% | ― | 2.67% | 20.58% | |
43 Neutral | $73.35M | -1.39 | -8.43% | ― | ― | ― |
* Healthcare Sector Average
BDMD
Baird Medical Investment Holdings
1.79
-3.67
-67.22%
APYX
Apyx Medical
3.06
1.90
163.79%
EDAP
EDAP TMS
3.47
1.32
61.62%
VANI
Vivani Medical
1.36
0.33
32.04%
XTNT
Xtant Medical Holdings
0.55
0.05
9.36%
ICCM
Icecure Medical
0.30
-0.73
-70.78%
Baird Medical Investment Holdings Corporate Events
Baird Medical Replaces Auditor Amid Ongoing Internal Control Weaknesses
Feb 10, 2026
Baird Medical Investment Holdings Limited, a China-based foreign private issuer reporting under U.S. securities rules, has its principal executive offices in Guangzhou and prepares financial statements under U.S. GAAP. The company is subject to SE...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.